Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Inclusion Criteria:

* Persistent or recurrent cutaneous T-cell lymphoma (CTCL) Stage IB-IVA as defined by TNM staging.
* Pathologic proven diagnosis (cytologically confirmed) of CTCL documented in patient history.
* Preserved organ function: Creatinine and/or Liver Function levels \<1.5 times institutional upper limits of normal (ULN).
* Adequate liver function as indicated by bilirubin \< or equal to 1.5 times ULN, ALT \< or equal to 2 times ULN, AST \< or equal to 2 times ULN.
* Albumin \>3.0 g/dL
* Adequate renal function as indicated by SCr \< or equal to 2.5 mg/dl.
* ECOG performance status between 0-2.
* Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period.
* Patients over the age of 18 who are willing and able to provide Informed Consent.

Exclusion Criteria:

* Pathology consistent with peripheral T-cell lymphoma.
* Stage IVB (visceral involvement with CTCL, other than lymph node involvement).
* History of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection.
* Patients who are pregnant or breast feeding.
* Allergy to or have history of allergy to diphtheria toxin or IL-2.
* Previous ONTAK® usage.
* Unstable cardiovascular disease.
* Patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. Exception: Clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy.
* Ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.